CHAPEL HILL, N.C., May 2, 2024 /PRNewswire/ — SonoVascular, Inc., a private medical device company focused on the development of its SonoThrombectomy™ System, a novel pharmaco-mechanical ultrasound facilitated thrombectomy system that utilizes microbubble-mediated cavitation as a core…
Author: Ken Dropiewski
MedRes opens medical device technology center in Carlsbad, CA
CARLSBAD, Calif., May 2, 2024 /PRNewswire/ — MedRes International, Inc. is pleased to announce the opening of its new technology development center in Carlsbad, California, in May 2024. The Carlsbad site is equipped to accelerate customer projects in the fields of cardiovascular…
IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., May 02, 2024 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
– Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accepted for the International Symposium on Amyloidosis in May 2024
Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2024, and updated financial guidance for its fiscal year ending September 30, 2024. “I’m incredibly proud of […]
Canon Medical Systems installs the first U.S. market Aquilion Serve SP CT Scanner with INSTINX Workflow Automation at Steinberg Diagnostic Medical Imaging (SDMI)
Tustin, Ca, May 01, 2024 (GLOBE NEWSWIRE) — Canon Medical Systems proudly announces the debut installation of the Aquilion Serve SP CT scanner with INSTINX, AI-driven workflow automation, in the United States at Steinberg Diagnostic Medical Imaging (SDMI), Las Vegas, NV. The Aquilion Serve SP CT scanner combines top-tier imaging […]
Arineta Launches New Chinese Venture, Arineta (Shandong) Medical Equipment Co., Addressing Rapid Rise in Cardiovascular Disease Deaths in China
Caesarea, Israel – April 30, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions through cutting-edge technology, is announcing its partnership with Shandong Yituo Medical Technology Development Co. Ltd. (SYMT), a JMC-invested company. Its new joint venture company, Arineta (Shandong) Medical Equipment Co. Ltd., is anticipating the installation of […]
Starlight Cardiovascular Awarded $2M NIH SBIR Phase II Grant to Develop Pediatric Cardiology Device
Award supports design and preclinical testing of Pulmonary Flow Restrictor for Congenital Heart Disease SAN DIEGO, May 1, 2024 /PRNewswire/ — Starlight Cardiovascular, Inc., a company developing pediatric cardiovascular medical devices, announced that it has been awarded a Small Business…
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) — BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
CVRx Reports First Quarter 2024 Financial and Operating Results
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2024.



